ATANASIO
PANDIELLA ALONSO
Investigador
María Elena
Díaz Rodríguez
Profesora Asociada
Publicaciones en las que colabora con María Elena Díaz Rodríguez (26)
2024
-
Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
Oncogenesis, Vol. 13, Núm. 1
-
Trastuzumab deruxtecan in breast cancer
Critical Reviews in Oncology/Hematology, Vol. 198
2022
-
Novel adcs and strategies to overcome resistance to anti-her2 adcs
Cancers, Vol. 14, Núm. 1
2020
-
Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms
Cancer Letters, Vol. 470, pp. 161-169
2019
-
Central role of cell cycle regulation in the antitumoral action of ocoxin
Nutrients, Vol. 11, Núm. 5
-
TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells
Cancer Letters, Vol. 453, pp. 34-44
2018
-
Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer
International Journal of Oncology, Vol. 53, Núm. 1, pp. 113-123
2017
-
Antitumoral effect of ocoxin in hepatocellular carcinoma
Oncology Letters, Vol. 14, Núm. 2, pp. 1950-1958
-
Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity
Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651
2016
-
Antitumoral effect of Ocoxin on acute myeloid leukemia
Oncotarget, Vol. 7, Núm. 5, pp. 6231-6242
-
Modulation of cereblon levels by anti-myeloma agents
Leukemia and Lymphoma, Vol. 57, Núm. 1, pp. 168-176
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
2014
-
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy
Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516
-
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease
Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305
2012
-
Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
Leukemia, Vol. 26, Núm. 8, pp. 1862-1869
2011
-
A modular approach to trim cellular targets in anticancer drug discovery
Bioorganic and Medicinal Chemistry Letters, Vol. 21, Núm. 22, pp. 6641-6645
-
Deficient spindle assembly checkpoint in multiple myeloma
PLoS ONE, Vol. 6, Núm. 11
2010
-
Multisite phosphorylation of Erk5 in mitosis
Journal of Cell Science, Vol. 123, Núm. 18, pp. 3146-3156
2008
-
Neuregulins and cancer
Clinical Cancer Research, Vol. 14, Núm. 11, pp. 3237-3241
2002
-
Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2
Molecular and Cellular Biology, Vol. 22, Núm. 1, pp. 270-285